长链非编码RNA与胶质瘤耐药机制相关性研究

胶质瘤是成人最常见的原发性脑肿瘤，手术切除后复发率高且对化疗药物产生耐药导致患者预后很差。目前，替莫唑胺（TMZ）化疗能有效地提高胶质瘤患者的总体生存率，但绝大多数患者在化疗过程中会逐渐产生耐药性从而缩减患者生存时间。因此，胶质瘤对TMZ耐药现已成为胶质瘤患者治疗中的主要障碍。近些年来大量证据表明一些长链非编码RNA（lncRNA）在胶质瘤化疗耐药中起着关键作用并且可能涉及多种机制来调节胶质瘤对TMZ的敏感性。本文旨在证明lncRNA在胶质瘤耐药机制和治疗中作用是一个新的研究方向，阐明胶质瘤化疗耐药的潜在机制，为逆转胶质瘤耐药提供新视角，同时也能促进胶质瘤精准医疗的发展。

Glioma, as the most common primary tumour of the central nervous system, has a high recurrence rate and resistance to chemotherapy drugs after surgical resection, resulting in poor prognosis. At present, temozolomide(TMZ) chemotherapy can effectively improve the overall survival rate of patients with glioma, but the vast majority of patients will gradually develop drug resistance during chemotherapy, reducing the survival time of patients. Glioma resistance to TMZ has become a major obstacle in the treatment of glioma patients. In recent years, a large amount of evidence has shown that long non-coding RNAs(LncRNA) play a key role in glioma chemotherapy resistance and may be involved in multiple mechanisms to regulate glioma sensitivity to TMZ. Therefore, The article aims to prove that the role of lncRNA in glioma drug resistance mechanism and treatment is a new research direction, clarify the potential mechanism of glioma chemotherapy drug resistance, provide a new perspective for the reversal of glioma drug resistance, and also promote the development of glioma precision medicine.